Hillsdale Investment Management Inc. Raises Stake in Royalty Pharma plc (NASDAQ:RPRX)

Hillsdale Investment Management Inc. grew its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,250 shares of the biopharmaceutical company’s stock after acquiring an additional 600 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Royalty Pharma were worth $619,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Brooklyn Investment Group boosted its position in shares of Royalty Pharma by 1,006.9% during the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 877 shares during the period. Riverview Trust Co boosted its stake in shares of Royalty Pharma by 3,953.3% during the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,186 shares during the last quarter. Fifth Third Bancorp grew its holdings in Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 997 shares during the period. Finally, Rakuten Securities Inc. grew its stake in shares of Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 1,003 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Up 0.1 %

RPRX opened at $33.75 on Tuesday. The firm has a 50-day simple moving average of $32.33 and a two-hundred day simple moving average of $28.75. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The company has a market capitalization of $19.46 billion, a PE ratio of 23.28, a price-to-earnings-growth ratio of 2.31 and a beta of 0.47. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.61%. The ex-dividend date was Friday, February 21st. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Analysts Set New Price Targets

Separately, TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.